New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:38 EDTMS, GS, FRX, ACTMorgan Stanley, Goldman said to switch fees for deal credit, Bloomberg says
Morgan Stanley (MS) and Goldman Sachs (GS) both decided last month that it was worth losing millions of dollars in fees to get credit on the $25B sale of Forest Laboratories (FRX) to Actavis (ACT), according to Bloomberg, citing four people with knowledge of the matter. The sources say that neither investment bank actually had a role on the deal. Reference Link
News For MS;GS;FRX;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 16, 2014
08:08 EDTACTActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
08:02 EDTACTIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
07:40 EDTGSGoldman: Net provisions for litigation for Q3 $194M vs. $142M a year ago
Subscribe for More Information
07:40 EDTGSGoldman Sachs says total staff increased 3% during Q3
Subscribe for More Information
07:39 EDTGSGoldman CEO: Client activity driven by improving U.S. economic conditions
Subscribe for More Information
07:38 EDTGSGoldman Sachs reports Common Equity Tier 1 ratio 11.8% at September 30
Subscribe for More Information
07:36 EDTGSGoldman Sachs raises quarterly dividend to 60c per share
Subscribe for More Information
07:36 EDTGSGoldman Sachs reports Q3 EPS $4.57, consensus $3.21
Reports Q3 revenue $8.39B, consensus $7.85B.
October 15, 2014
15:28 EDTGSNotable companies reporting before tomorrow's open
Subscribe for More Information
15:02 EDTGSGoldman Sachs October 177 straddle priced for 3.7% move into Q3
Subscribe for More Information
12:23 EDTMSMorgan Stanley October volatility elevated into Q3 and outlook
Subscribe for More Information
October 14, 2014
08:08 EDTGSGoldman Sachs October volatility elevated into Q3 and outlook
Subscribe for More Information
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
07:15 EDTGSNational Association of Corporate Directors to hold a conference
Subscribe for More Information
06:44 EDTGS, MSRegulators seeking banks' auto loan data, Reuters reports
Subscribe for More Information
06:37 EDTGS, MSBlackRock, Morgan Stanley to buy shares in Link Net, WSJ reports
Subscribe for More Information
06:25 EDTMSMorgan Stanley may not close Rosneft deal, WSJ reports
Subscribe for More Information
October 12, 2014
13:03 EDTGS, MSBanks agree on derivatives procedures for future crisis scenario, WSJ says
Meeting at the Federal Reserve in Washington, top banking executives from 18 large U.S., European and Japanese banks agreed in principle to wait up to 48 hours before seeking to terminate derivatives contracts and collect associated payments from a troubled financial institution, says the Wall Street Journal. Publicly traded companies in the space include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Reference Link
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use